Reported Monday, Insmed To Discuss Topline Results From Phase 3 ASPEN Study Of Brensocatib In Patients With Bronchiectasis
Portfolio Pulse from Benzinga Newsdesk
Insmed is set to discuss the topline results from its Phase 3 ASPEN study of Brensocatib in patients with bronchiectasis. A conference call will take place on Tuesday, May 28, 2024, at 8:00 am ET.
May 28, 2024 | 7:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Insmed will discuss the results of its Phase 3 ASPEN study for Brensocatib, which could significantly impact its stock price depending on the outcomes. The conference call is scheduled for May 28, 2024.
The results of the Phase 3 ASPEN study are critical for Insmed as they could determine the future of Brensocatib in treating bronchiectasis. Positive results could lead to a significant stock price increase, while negative results could have the opposite effect.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100